Age at screening (years) | No. of women screened in the age group | No. of HPV-positive (% of women screened) (95% CI) | Colposcopy attendance among HPV-positive | Histopathology resultsb (% of women attending colposcopyc) (95% CI) | Yield of the screening effortb (% of total women screened) | ||
---|---|---|---|---|---|---|---|
CIN2+ | CIN3+ | CIN2+ | CIN3+ | ||||
30–34 | 2553 | 476 (18.6%) (17.2–20.2%) | 393 (82.6%) | 26 (6.6%) (4.4–9.6%) | 14 (3.6%) (2.0–5.9%) | 1.0% | 0.5% |
35–39 | 2646 | 411 (15.5%) (14.2–17.0%) | 354 (86.1%) | 18 (5.1%) (3.0–7.9%) | 10 (2.8%) (1.4–5.1%) | 0.7% | 0.4% |
40–44 | 2282 | 351 (15.4%) (13.9–16.9%) | 309 (88.0%) | 12 (3.9%) (2.0–6.7%) | 5 (1.6%) (0.5–3.7%) | 0.5% | 0.2% |
45–49 | 1479 | 213 (14.4%) (12.7–16.3%) | 194 (91.1%) | 15 (7.7%) (4.4–12.4%) | 7 (3.6%) (1.5–7.3%) | 1.0% | 0.5% |
Total | 8960a | 1451 (16.2%) (15.4–17.0%) | 1250 (86.1%) | 71 (5.7%) (4.5–7.1%) | 36 (2.9%) (2.0–4.0%) | 0.8% | 0.4% |